ID 119031166
Alternative Names: ID-11903; ID-119031166; ID119031166MLatest Information Update: 26 Jul 2024
At a glance
- Originator Ildong Pharmaceutical
- Class Hepatoprotectants; Isoxazoles; Small molecules
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 09 Jul 2024 IlDong Pharmaceutical terminates a phase I trial in Non-alcoholic steatohepatitis (In volunteers) in USA (PO), since the sponsor have decided to cancel the trial (NCT05604287)
- 09 Nov 2022 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in USA (PO) (NCT05604287)
- 04 Nov 2022 Pharmacodynamics and pharmacokinetics data from a preclinical study presented at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases